SIP
ALPN

Stoneridge Investment Partners’s Alpine Immune Sciences Inc ALPN Stock Holding History

Stoneridge Investment Partners’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,391
Closed -$30K – 358
2016
Q4 		$30K Hold
3,391
– – ﹤0.01% 283
2016
Q3 		$110K Sell
3,391
-17
-0.5% -$414 0.02% 258
2016
Q2 		$63K Hold
3,408
– – 0.01% 275
2016
Q1 		$57K Sell
3,408
-1,439
-30% -$28.8K 0.01% 285
2015
Q4 		$150K Buy
+4,847
New +$165K 0.02% 267

Other funds holding ALPN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Stoneridge Investment Partners's ALPN Position: Q1 2017 in Review

Stoneridge Investment Partners sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2017, closing a stake of 3,391 shares — an estimated $30K sold.

Stoneridge Investment Partners first reported a position in ALPN in Q4 2015 and held it in 5 quarters. The position peaked at $150K in Q4 2015. 28 funds tracked by Wall St. Rank hold ALPN as of Q1 2017.

  • Stoneridge Investment Partners reported no remaining Alpine Immune Sciences Inc position as of Q1 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 3,391 Alpine Immune Sciences Inc shares in Q1 2017, an estimated $30K.
  • Stoneridge Investment Partners first reported a position in Alpine Immune Sciences Inc in Q4 2015 and held it in 5 quarters.
  • Stoneridge Investment Partners's Alpine Immune Sciences Inc position peaked at $150K in Q4 2015.
  • 28 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2017.

Based on Stoneridge Investment Partners's 13F filing for Q1 2017, filed 1 May 2017.